Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

[1]  E. Plimack,et al.  Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. , 2023, Journal of Clinical Oncology.

[2]  C. Porta,et al.  Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). , 2023, Journal of Clinical Oncology.

[3]  M. Burotto,et al.  Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. , 2023, The New England journal of medicine.

[4]  Wenxin Xu,et al.  First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma. , 2023, Hematology/oncology clinics of North America.

[5]  R. Motzer,et al.  Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma , 2023, ESMO open.

[6]  Alessandro Rizzo,et al.  An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma , 2023, Expert opinion on drug safety.

[7]  C. Porta,et al.  Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. , 2023, Journal of Clinical Oncology.

[8]  Ruifeng Xu,et al.  Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1–Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Ying Cheng,et al.  Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  O. Kucuk,et al.  Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials , 2022, Cancers.

[11]  Q. Geng,et al.  Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China , 2022, Frontiers in Immunology.

[12]  C. Kollmannsberger,et al.  Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review , 2022, Therapeutic Advances in Medical Oncology.

[13]  R. Motzer,et al.  Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. , 2021, JAMA oncology.

[14]  F. Zhou,et al.  Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 , 2021, Clinical Cancer Research.

[15]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[16]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[17]  A. Yıldırım,et al.  Influence of border-age on survival of sporadic renal cell carcinoma: young adults versus octogenarians , 2020, International Urology and Nephrology.

[18]  Haifeng Song,et al.  Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial , 2020, Clinical Cancer Research.

[19]  C. Porta,et al.  Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[20]  K. Flaherty,et al.  Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[22]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[23]  Haifeng Song,et al.  Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients , 2019, Journal of Hematology & Oncology.

[24]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[25]  T. Choueiri,et al.  Characterization of Patients With Poor‐Risk Metastatic Renal‐Cell Carcinoma: Results From a Pooled Clinical Trials Database , 2017, Clinical genitourinary cancer.

[26]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[27]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[28]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.